Enhancement of liver parenchyma after injection of hepatocyte‐specific MRI contrast media: A comparison of gadoxetic acid and gadobenate dimeglumine

Purpose:

To compare enhancement of liver parenchyma in MR imaging after injection of hepatocyte‐specific contrast media.

Materials and Methods:

Patients (n = 295) with known/suspected focal liver lesions randomly received 0.025 mmol gadoxetic acid/kg body weight or 0.05 mmol gadobenate dimeglumine/kg body weight by means of bolus injection. MR imaging was performed before and immediately after injection, and in the delayed phase at approved time points (20 min after injection of gadoxetic acid and 40 min after injection of gadobenate dimeglumine). The relative liver enhancement for the overall population and a cirrhotic subgroup was compared in T1‐weighted GRE sequences. An independent radiologist performed signal intensity measurements. Enhancement ratios were compared using confidence intervals (CIs).

Results:

The relative liver enhancement in the overall population was superior with gadoxetic acid (57.24%) versus gadobenate dimeglumine (32.77%) in the delayed‐imaging phase. The enhancement ratio between the contrast media was statistically significant at 1.75 (95% CI: 1.46–2.13). In the delayed phase, the enhancement of cirrhotic liver with gadoxetic acid (57.00%) was comparable to that in the overall population. Enhancement with gadobenate dimeglumine was inferior in cirrhotic liver parenchyma (26.85%).

Conclusion:

In the delayed, hepatocyte‐specific phase, liver enhancement after injection of gadoxetic acid was superior to that obtained with gadobenate dimeglumine. J. Magn. Reson. Imaging 2010; 31: 356–364. © 2010 Wiley‐Liss, Inc.

     

Optimized high-resolution contrast-enhanced hepatobiliary imaging at 3 tesla: a cross-over comparison of gadobenate dimeglumine and gadoxetic acid

Purpose:

To evaluate the signal to noise ratio (SNR) and contrast to noise ratio (CNR) performance of 0.05 mmol/kg gadoxetic acid and 0.1 mmol/kg gadobenate dimeglumine for dynamic and hepatobiliary phase imaging. In addition, flip angles (FA) that maximize relative contrast‐to‐noise performance for hepatobiliary phase imaging were determined.

Materials and Methods:

A cross‐over study in 10 volunteers was performed using each agent. Imaging was performed at 3 Tesla (T) with a 32‐channel phased‐array coil using breathheld 3D spoiled gradient echo sequences for SNR and CNR analysis, and for FA optimization of hepatobiliary phase imaging.

Results:

Gadobenate dimeglumine (0.1 mmol/kg) had superior SNR performance during the dynamic phase, statistically significant for portal vein and hepatic vein in the portal venous and venous phase (for all, P < 0.05) despite twice the approved dose of gadoxetic acid (0.05 mmol/kg), while gadoxetic acid had superior SNR performance during the hepatobiliary phase. Optimal FAs for hepatobiliary phase imaging using gadoxetic acid and gadobenate dimeglumine were 25–30° and 20–30° for relative contrast liver versus muscle (surrogate for nonhepatocellular tissues), and 45° and 20° (relative contrast liver versus biliary structures), respectively.

Conclusion:

Gadobenate dimeglumine may be preferable for applications that require dynamic phase imaging only, while gadoxetic acid may be preferable when the hepatobiliary phase is clinically important. Hepatobiliary phase imaging with both agents benefits from flip angle optimization. J. Magn. Reson. Imaging 2011;. © 2011 Wiley‐Liss, Inc.     

Multicenter,double‐blind,randomized, intra‐individual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine in MRI of brain tumors at 3 tesla

Purpose

To prospectively compare 0.1 mmol/kg doses of gadobenate dimeglumine and gadopentetate dimeglumine for contrast‐enhanced MRI of brain lesions at 3 Tesla (T).

Materials and Methods

Forty‐six randomized patients underwent a first examination with gadobenate dimeglumine (n = 23) or gadopentetate dimeglumine (n = 23) and then, after 2–7 days, a second examination with the other agent. Contrast administration (volume, rate), sequence parameters (T1wSE; T1wGRE), and interval between injection and image acquisition were identical for examinations in each patient. Three blinded neuroradiologists evaluated images qualitatively (lesion delineation, lesion enhancement, global preference) and quantitatively (lesion‐to‐brain ratio [LBR], contrast‐to‐noise ratio [CNR], % lesion enhancement). Differences were assessed using Wilcoxon's signed‐rank test. Reader agreement was determined using kappa (κ) statistics.

Results

There were no demographic differences between groups. The three readers preferred gadobenate dimeglumine globally in 22 (53.7%), 21 (51.2%), and 27 (65.9%) patients, respectively, compared with 0, 1, and 0 patients for gadopentetate dimeglumine. Similar significant (P < 0.001) preference was expressed for lesion border delineation and enhancement. Reader agreement was consistently good (κ = 0.48–0.64). Significantly (P < 0.05) higher LBR (+43.5– 61.2%), CNR (+51.3–147.6%), and % lesion enhancement (+45.9–49.5%) was noted with gadobenate dimeglumine.

Conclusion

Brain lesion depiction at 3T is significantly improved with 0.1 mmol/kg gadobenate dimeglumine. J. Magn. Reson. Imaging 2009;29:760–767. © 2009 Wiley‐Liss, Inc.     

Characterization of hepatic adenoma and focal nodular hyperplasia with gadoxetic acid

Purpose:

To characterize imaging features of histologically proven hepatic adenoma (HA) as well as histologically and/or radiologically proven focal nodular hyperplasia (FNH) using delayed hepatobiliary MR imaging with 0.05 mmol/kg gadoxetic acid.

Materials and Methods:

Five patients with six HAs with histological correlation were retrospectively identified on liver MRI studies performed with gadoxetic acid, and T1‐weighted imaging acquired during the delayed hepatobiliary phase. Additionally, 23 patients with 34 radiologically diagnosed FNH lesions (interpreted without consideration of delayed imaging) were identified, two of which also had histological confirmation. Signal intensity ratios relative to adjacent liver were measured on selected imaging sequences.

Results:

All six hepatic adenomas (100%), which had histological confirmation, demonstrated hypointensity relative to adjacent liver on delayed imaging. Furthermore, all of the FNH (including 34 radiologically proven, 2 of which were also histologically proven) were either hyperintense (23/34, 68%) or isointense (11/34, 32%) relative to the adjacent liver on delayed imaging. None of the FNHs were hypointense relative to liver.

Conclusion:

Distinct imaging characteristics of HA versus FNH on delayed gadoxetic acid‐enhanced MRI, with adenomas being hypointense and FNH being iso‐ or hyperintense on delayed imaging may improve specificity for characterization, and aid in the differentiation of these two lesions. J. Magn. Reson. Imaging 2012;36:686–696. © 2012 Wiley Periodicals, Inc.     

Comparison of the Enhancement Pattern of Hepatic Hemangioma on Magnetic Resonance Imaging Performed With Gd-EOB-DTPA Versus Gd-BOPTA

PurposeTo compare magnetic resonance imaging (MRI) findings with gadoxetic acid and gadobenate dimeglumine for the diagnosis of hepatic hemangiomas.Materials and MethodsIn this retrospective study, we included 26 hemangiomas (mean size was 14 mm ± 10 mm) in 19 patients (mean age 60 ± 14 years) scanned with both gadobenate dimeglumine MRI and gadoxetic acid MRI. For each patient, we collected multiple lesion variables including location, number, size and enhancement pattern on arterial, portal venous, 3-minute and hepatobiliary phases with both gadoxetic acid and gadobenate dimeglumine. The enhancement pattern with the two contrast agents was then compared.ResultsThe typical enhancement pattern of hepatic hemangiomas was more common—though not statistically significant—with gadobenate dimeglumine compared to gadoxetic acid (57% [15 of 26] vs 42% [11 of 26], respectively; P = 0.4057 for both peripheral globular discontinuous enhancement in the arterial phase and centripetal fill-in in the portal venous phase). A significantly higher number of hemangiomas showed centripetal fill-in or hyperintensity in the 3-minute phase with gadobenate dimeglumine compared to gadoxetic acid (88% [23 of 26) vs 58% [15 of 26]; P = 0.0266). A pseudo washout sign in the 3-minute phase was detected in one of the 5 flash-filling hemangiomas with gadoxetic acid, but not gadobenate dimeglumine. All hemangiomas were hypointense in the hepatobiliary phase with both gadobenate dimeglumine and gadoxetic acid.ConclusionsThe enhancement pattern of hepatic hemangiomas may vary depending on the hepatobiliary agent, with more frequent lack of the typical pattern with gadoxetic acid compared to gadobenate dimeglumine.     

Gadoxetic acid disodium-enhanced magnetic resonance imaging for biliary and vascular evaluations in preoperative living liver donors: comparison with gadobenate dimeglumine-enhanced MRI

Purpose

To compare gadoxetic acid disodium (Gd‐EOB‐DTPA)‐enhanced magnetic resonance imaging (MRI) with gadobenate dimeglumine (Gd‐BOPTA)‐enhanced MRI in preoperative living liver donors for the evaluation of vascular and biliary variations.

Materials and Methods

Sixty‐two living liver donors who underwent preoperative MRI were included in this study. Thirty‐one patients underwent MRI with Gd‐EOB‐DTPA enhancement, and the other 31 underwent MRI with Gd‐BOPTA enhancement. Two abdominal radiologists retrospectively reviewed dynamic T1‐weighted and T1‐weighted MR cholangiography images and ranked overall image qualities for the depiction of the hepatic artery, portal vein, hepatic vein, and bile duct on a 5‐point scale and determined the presence and types of normal variations in each dynamic phase. Semiquantitative analysis for bile duct visualization was also conducted by calculating bile duct‐to‐liver contrast ratios.

Results

No statistical differences were found between the two contrast media in terms of hepatic artery or bile duct image quality by the two reviewers, or in terms of portal vein image quality by one reviewer (P > 0.05). Gd‐BOPTA provided better image qualities than Gd‐EOB‐DTPA for the depiction of hepatic veins by both reviewers, and for the depiction of portal veins by one reviewer (P < 0.01). The two contrast media‐enhanced images had similar bile duct‐to‐liver contrast ratios (P > 0.05). Regarding diagnostic accuracies with hepatic vascular/biliary branching types, no significant differences were observed between the two contrast media (P > 0.05).

Conclusion

Gd‐EOB‐DTPA could be as useful as Gd‐BOPTA for the preoperative evaluation of living liver donors, and has the advantage of early hepatobiliary phase image acquisition. J. Magn. Reson. Imaging 2011;33:149–159. © 2010 Wiley‐Liss, Inc.     

Enhancement effects of hepatic dynamic MR imaging at 3.0 T and 1.5 T using gadoxetic acid in a phantom study: comparison with gadopentetate dimeglumine

To identify the optimum sequence at gadoxetic acid enhanced hepatic dynamic magnetic resonance imaging in the arterial phase, we studied phantoms that contained gadoxetic acid or gadopentetate dimeglumine diluted in human blood. We obtained magnetic resonance images at 3.0 T and 1.5 T with one vendor (Siemens) using 3D‐gradient echo (GRE)‐, 2D‐fast low angle shot (FLASH)‐, and turbo spin echo sequences. Contrast ratio was highest for 3D‐GRE; at both 3.0 T and 1.5 T it was superior when the contrast agent was gadoxetic acid. With both gadoxetic acid and gadopentetate dimeglumine, contrast ratio peaked at around 5‐and 2 mmol/L on 3D‐GRE‐ and 2D‐FLASH images, respectively. Compared with gadopentetate dimeglumine, at 3.0 T, the peak contrast ratio of gadoxetic acid was 14.1% better on 3D‐GRE images and 14.0% better on 2D‐FLASH images; at 1.5 T it was 16.4% better on 3D‐GRE‐ and 5.7% better on 2D‐FLASH images. With respect to the magnetic field strength, at 3.0 T the peak contrast ratio of gadoxetic acid was 6.0% better than at 1.5 T on 3D‐GRE images and 49.5% better on 2D‐FLASH images; it was 8.5% better on 3D‐GRE‐ and 44.6% better on 2D‐FLASH images than when the contrast agent was gadopentetate dimeglumine. Thus, gadoxetic acid yielded better enhancement on 3D‐GRE images acquired at 3.0 T than at 1.5 T and enhancement was better than that obtained with gadopentetate dimeglumine at the same concentration. Magn Reson Med 66:213–218, 2011. © 2011 Wiley‐Liss, Inc.     

Evaluation of the hepatocyte-specific contrast agent gadobenate dimeglumine for MR imaging of acute hepatitis in a rat model

This work was conducted to test the hypothesis that contrast-enhanced MRI with hepatocyte-specific contrast agents facilitates quantitation and mapping of diffuse liver diseases such as hepatitis and cirrhosis. Gadobenate dimeglumine (Gd-BOPTA/Dimeg, Bracco SpA, Milano, Italy) is a new paramagnetic hepatocytespecific contrast agent currently undergoing clinical trials. We have assessed the usefulness of gadobenate dimeglumine for the diagnosis of diffuse liver diseases in a rat model of chemically induced hepatitis. The study was based on the measurements of in vivo liver relaxation times as well as on the acquisition of standard SE images. Acute hepatitis considerably reduced the degree of T1 shortening of liver parenchyma caused by intravenous injection of .25 mmol/kg of gadobenate dimeglumine. Analogously, the enhancement of the MRI signal intensity of the liver of rats with hepatitis observed in T1-weighted spin-echo (SE) images was inferior, in terms of both strength and duration, to that recorded in control rats at doses of .25 mmol/kg and .075 mmol/kg of gadobenate dimeglumine. Our results show that gadobenate dimeglumine enhanced MR imaging has the potential for visualization of hepatitis and for assessment of liver function. Our conclusions differ from those previously published on this subject by other authors. The reasons that led to differing conclusions are discussed.     

Gadoxetic Acid (Gd-EOB-DTPA)-Enhanced MRI versus Gadobenate Dimeglumine (Gd-BOPTA)-Enhanced MRI for Preoperatively Detecting Hepatocellular Carcinoma: an Initial Experience

Objective

This study was designed to compare the diagnostic performance of gadoxetic acid-enhanced magnetic resonance imaging (MRI) with gadobenate dimeglumine-enhanced MRI for preoperatively detecting hepatocellular carcinoma (HCC).

Materials and Methods

Eighteen consecutive patients (17 men and one woman, age range: 31-73 years) with 22 HCCs underwent examinations with gadoxetic acid enhanced MRI and gadobenate dimeglumine-enhanced MRI on a 3.0-Tesla unit. The diagnosis of HCC was established after surgical resection and pathological conformation. Three observers independently reviewed each MR image in a random order on a tumor-by-tumor basis. The diagnostic accuracy of these techniques for the detection of HCC was assessed by performing an alternative free-response receiver operating characteristic (ROC) analysis. The sensitivity and positive predictive values were evaluated.

Results

The average value of the area under the ROC curve (Az) for gadoxetic acid enhanced MRI (0.887) was not significantly different from the Az (0.899) for gadobenate dimeglumine-enhanced MRI (p > 0.05). The overall sensitivities of gadoxetic acid enhanced MRI and gadobenate dimeglumine-enhanced MRI were 80% and 83%, respectively, with no significant difference (p > 0.05). The differences of the positive predictive values for the two contrast agents for each observer were not statistically significant (p > 0.05).

Conclusion

The diagnostic performance of gadoxetic acid-enhanced MRI and gadobenate dimeglumine-enhanced MRI for preoperatively detecting HCC is quite similar.     

Gadobenate dimeglumine-enhanced MRI of the breast: analysis of dose response and comparison with gadopentetate dimeglumine

OBJECTIVE: The purpose of this study was to evaluate the clinical efficacy and dose response relationship of three doses of gadobenate dimeglumine for MRI of the breast and to compare the results with those obtained after a dose of 0.1 mmol/kg of body weight of gadopentetate dimeglumine. SUBJECTS AND METHODS. Gadobenate dimeglumine at 0.05, 0.1, or 0.2 mmol/kg of body weight or gadopentetate dimeglumine at 0.1 mmol/kg of body weight was administered by IV bolus injection to 189 patients with known or suspected breast cancer. Coronal three-dimensional T1-weighted gradient-echo images were acquired before and at 0, 2, 4, 6, and 8 min after the administration of the dose. Images were evaluated for lesion presence, location, size, morphology, enhancement pattern, conspicuity, and type. Lesion signal intensity-time curves were acquired, and lesion matching with on-site final diagnosis was performed. A determination of global lesion detection from unenhanced to contrast-enhanced and combined images was performed, and evaluations were made of the diagnostic accuracy for lesion detection and characterization. A full safety evaluation was conducted. RESULTS: Significant dose-related increases in global lesion detection were noted for patients who received gadobenate dimeglumine (p < 0.04, all evaluations). The sensitivity for detection was comparable for 0.1 and 0.2 mmol/kg of gadobenate dimeglumine, and specificity was highest with the 0.1 mmol/kg dose. Higher detection scores and higher sensitivity values for lesion characterization were found for 0.1 mmol/kg of gadobenate dimeglumine compared with 0.1 mmol/kg of gadopentetate dimeglumine, although more variable specificity values were obtained. No differences in safety were observed, and no serious adverse events were reported. CONCLUSION: Gadobenate dimeglumine is a capable diagnostic agent for MRI of the breast. Although preliminary, our results suggest that 0.1 mmol/kg of gadobenate dimeglumine may offer advantages over doses of 0.05 and 0.2 mmol/kg of gadobenate dimeglumine and 0.1 mmol/kg of gadopentetate dimeglumine for breast lesion detection and characterization.     

Characterization of hyperintense nodules on precontrast T1-weighted MRI: utility of gadoxetic acid-enhanced hepatocyte-phase imaging

Purpose:

To evaluate the utility of gadoxetic acid‐enhanced hepatocyte‐phase magnetic resonance imaging (MRI) in characterization of T1‐weighted hyperintense nodules within cirrhotic liver.

Materials and Methods:

This retrospective study was approved by our Institutional Review Board. Thirty‐four nodules hyperintense in unenhanced T1‐weighted MRI with histopathological confirmation from a collection of 19 patients were included. Tumor size, signal intensity on T1‐weighted, and T2‐weighted imaging as well as enhancement patterns on contrast‐enhanced dynamic/hepatocyte‐phase imaging were recorded. Receiver operating characteristic (ROC) analysis was used to evaluate the diagnostic performance of hepatocyte‐phase imaging.

Results:

Evaluation of the nodules with standard of reference revealed 15 dysplastic nodules (DN), seven well‐differentiated hepatocellular carcinomas (wHCC), and 12 moderately differentiated HCCs (mHCC). The mean size of dysplastic nodules was smaller than that of HCCs (P < 0.001). Using the HCC criteria (T2W or arterial enhancement followed with portal venous washout), 11/19 HCC were correctly characterized. Using solely hypointensity (compared to the surrounding liver parenchyma) during the hepatocyte phase as the criterion, 18/19 HCC were correctly characterized. There were seven additional HCCs diagnosed with hepatocyte‐phase imaging (P = 0.02).

Conclusion:

Gadoxetic acid‐enhanced MRI with hepatocyte‐phase imaging is superior to gadoxetic acid‐enhanced MRI with conventional criteria alone in characterization of T1W hyperintense nodules. J. Magn. Reson. Imaging 2011;33:625–632. © 2011 Wiley‐Liss, Inc.     

Comparison of two different injection rates of gadoxetic acid for arterial phase MRI of the liver

Purpose:

To compare two different injection rates for gadoxetic acid‐enhanced hepatic arterial phase images on hepatic dynamic MRI.

Materials and Methods:

Hepatic arterial phase images were obtained after an intravenous bolus injection of gadoxetic acid at a rate of 1 mL/second in 62 patients and 2 mL/second in 64 patients on a 3 Tesla MR scanner using a test‐bolus injection method. The signal‐to‐noise ratios (SNR) of the liver, portal vein, hepatic vein, aorta, spleen and pancreas were measured. The contrast‐to‐noise ratio (CNR) of hypervascular hepatic tumors was calculated. Two radiologists independently scored items to evaluate image quality of hepatic arterial phase and detected hypervascular hepatocellular carcinoma (HCC).

Results:

The SNR of the aorta on the arterial phase images was significantly higher in the 1 mL/second group (235.43 ± 82.59) than in the 2 mL/second group (190.94 ± 96.90, P < 0.05). The SNRs of the liver, spleen and pancreas, the CNRs of hypervascular hepatic tumors, the detection rate of hypervascular HCC and subjective ratings for the optimal arterial enhancement were comparable between the two groups.

Conclusion:

Injection rates of 2 mL/second and 1 mL/second provided comparable image qualities on arterial phase images of hepatic dynamic MRI using gadoxetic acid. J. Magn. Reson. Imaging 2010; 31: 365–372. © 2010 Wiley‐Liss, Inc.     

Gadoxetic acid-enhanced MRI findings of early hepatocellular carcinoma as defined by new histologic criteria

Purpose:

To describe the imaging features of early hepatocellular carcinoma (HCC) on gadoxetic acid‐enhanced MRI (Gd‐EOB‐MRI) in comparison with multidetector computed tomography (MDCT) examinations.

Materials and Methods:

We analyzed imaging findings of 19 pathologically proven early HCC lesions in 15 patients who underwent both MDCT and Gd‐EOB‐MRI at 3.0 Tesla (T) units before surgery. MRI included in‐phase and out‐of‐phase T1‐weighted dual‐echo gradient‐recalled‐echo sequences, dynamic T1‐weighted images before and after bolus injection of gadoxetic acid disodium, fat‐saturated T2‐weighted fast spin‐echo sequences, and T1‐weighted hepatobiliary phase images 20 min after contrast injection. Two radiologists retrospectively evaluated the signal intensities and enhancement features on MRI and MDCT.

Results:

None of the lesions displayed arterial enhancement and washout on MDCT. On Gd‐EOB‐MRI, six (32%) lesions showed T2‐hyperintensity, five (26%) lesions showed signal drop on opposed‐phase. Three lesions (16%) showed arterial enhancement and washout. Twelve (63%), 13 (68%), and 15 (79%) lesions were hypointense on hepatic venous, equilibrium, and hepatobiliary phase, respectively.

Conclusion:

Most early HCCs did not show arterial enhancement and washout pattern on both MDCT and Gd‐EOB‐MRI. Gd‐EOB‐MRI may provide several ancillary findings for diagnosis of early HCC such as decreased hepatobiliary uptake, T2 hyperintensity and signal drop in opposed phase. J. Magn. Reson. Imaging 2012;393‐398. © 2011 Wiley Periodicals, Inc.     

Differentiating combined hepatocellular and cholangiocarcinoma from mass-forming intrahepatic cholangiocarcinoma using gadoxetic acid-enhanced MRI

Purpose:

To examine the differential features of combined hepatocellular and cholangiocarcinoma (HCC‐CC) from mass‐forming intrahepatic cholangiocarcinoma (ICC) on gadoxetic acid‐enhanced MRI.

Materials and Methods:

Forty patients with pathologically proven combined HCC‐CC (n = 20) and ICCs (n = 20) who had undergone gadoxetic acid‐enhanced MRI were enrolled in this study. MR images were analyzed for the shape of lesions, hypo‐ or hyperintense areas on the T2‐weighted image (T2WI), rim enhancement during early dynamic phases, and central enhancement with hypointense rim (target appearance) on the 10‐min and 20‐min hepatobiliary phase (HBP). The significance of these findings was determined by the χ² test.

Results:

Irregular shape and strong rim enhancement during early dynamic phases, and absence of target appearance on HBP favored combined HCC‐CCs (P < 0.05). Lobulated shape, weak peripheral rim enhancement, and the presence of complete target appearance on the 10‐min and 20‐min HBP favored ICCs (P < 0.05). However, 10 CC‐predominant type of combined HCC‐CC showed complete or partial target appearance on 10‐min HBP.

Conclusion:

The shape of tumors, degree of rim enhancement during early dynamic phases, and target appearance on HBP were valuable for differentiating between combined HCC‐CC and mass‐forming ICC on gadoxetic acid‐enhanced MRI. J. Magn. Reson. Imaging 2012;36:881–889. © 2012 Wiley Periodicals, Inc.     

High resolution navigated three-dimensional T(1) -weighted hepatobiliary MRI using gadoxetic acid optimized for 1.5 tesla

Purpose:

To determine optimal delay times and flip angles for T1‐weighted hepatobiliary imaging at 1.5 Tesla (T) with gadoxetic acid and to demonstrate the feasibility of using a high‐resolution navigated optimized T1‐weighted pulse sequence to evaluate biliary disease.

Materials and Methods:

Eight healthy volunteers were scanned at 1.5T using a T1‐weighted three‐dimensional (3D)‐SPGR pulse sequence following the administration of 0.05 mmol/kg of gadoxetic acid. Navigator‐gating enabled acquisition of high spatial resolution (1.2 × 1.4 × 1.8 mm³, interpolated to 0.7 × 0.7 × 0.9 mm³) images in approximately 5 min of free‐breathing. Multiple breath‐held acquisitions were performed at flip angles between 15° and 45° to optimize T1 weighting. To evaluate the performance of this optimized sequence in the setting of biliary disease, the image quality and biliary excretion of 51 consecutive clinical scans performed to assess primary sclerosing cholangitis (PSC) were evaluated.

Results:

Optimal hepatobiliary imaging occurs at 15–25 min, using a 40° flip angle. The image quality and visualization of biliary excretion in the PSC scans were excellent, despite the decreased liver function in some patients. Visualization of reduced excretion often provided diagnostic information that was unavailable by conventional magnetic resonance cholangiopancreatography (MRCP).

Conclusion:

High‐resolution navigated 3D‐SPGR hepatobiliary imaging using gadoxetic acid and optimized scan parameters is technically feasible and can be clinically useful, even in patients with decreased hepatobiliary function. J. Magn. Reson. Imaging 2012;36:890–899. © 2012 Wiley Periodicals, Inc.     

Bone metastases: evaluation of acuity of lesions using dynamic gadolinium-chelate enhancement, preliminary results

Purpose:

To evaluate whether enhancement on serial dynamic gadolinium‐enhanced abdominal–pelvic MR imaging (DCE‐MRI) can determine the acuity of bone metastases.

Materials and Methods:

Twenty consecutive patients who underwent abdominal–pelvic DCE‐MRI for evaluation/staging of a proven cancer and had bone metastases were included. Two radiologists analyzed in consensus 59 DCE‐MRIs of these patients. Region of interest measurements were performed in up to three lesions on noncontrast T1‐weighted, serial hepatic arterial dominant phase (HADP), early hepatic venous phase (EHVF), and interstitial phase (IP) postgadolinium images, and the percentage enhancement of 134 lesions was calculated. The coordinator separately and retrospectively sorted the lesions into three groups based on the imaging and clinical information: acute/active, subacute, and chronic metastases.

Results:

The mean percentage enhancement of the bone metastases classified as acute/active, subacute, and chronic in the HADP, EHVP and IP were respectively (%): 134, 107, 99; 87, 86, 87; and 39, 65, 73. In the HADP, acute/active lesions enhanced significantly more than both subacute (1.53‐fold) and chronic (3.4‐fold) lesions (P < 0.01). Time intensity curves were significantly different between these three entities as well.

Conclusion:

The enhancement on arterial phase images and the time–intensity curves were different for acute/active, subacute, and chronic bone metastases. J. Magn. Reson. Imaging 2011;. © 2011 Wiley‐Liss, Inc.     

Phase II double-blind, dose-ranging clinical evaluation of gadobenate dimeglumine in focal liver lesions: with analysis of liver and kidney signal change on early and delayed imaging

To evaluate the effect of contrast dose using gadobenate dimeglumine, 30 patients with focal liver lesions documented by computed tomography or ultrasound were studied by magnetic resonance imaging at 1.5 T. Patients received one of four doses of gadobenate dimeglumine (0.025, 0.05, 0.1, or 0.2 mmol/kg) or saline. The order of dosage was randomized, with both the physician and patient blinded to the administered dose. Scans were obtained before, immediately following injection, and after 80 minutes of delay. Enhancement effects were quantified by region of interest measurements. Films were also reviewed in a randomized prospective fashion by an abdominal radiologist blinded to contrast dose and diagnosis. Higher doses led to a statistically significant improvement in enhancement of normal liver, both on immediate (P = 0.01 for the comparison of 0.1 and 0.2 mmol/kg immediately post-contrast) and delayed scans (P = 0.003 for the same comparison). Liver-lesion contrast-to-noise ratio also increased with dose, although results for most comparisons by dose were not statistically significant. Scans following gadobenate dimeglumine injection were judged to provide additional diagnostic confidence sufficient to affect patient management in 10 of 24 cases. In seven cases this information was provided by dynamic scans, in one case by delayed scans, and in two cases by both dynamic and delayed scans. In 2 of the 10 cases the dose was 0.025 mmol/kg, in 2 cases 0.05 mmol/kg, in 3 cases 0.1 mmol/kg, and in 3 cases 0.2 mmol/kg. Gadobenate dimeglumine is effective for imaging of focal liver lesions at a range of doses, with trends toward improved diagnostic information at higher doses.     

Decreased incidence of NSF in patients on dialysis after changing gadolinium contrast‐enhanced MRI protocols

Purpose:

To retrospectively determine the incidence of nephrogenic systemic fibrosis (NSF) in patients on dialysis administered either a lower dose high‐relaxivity linear gadolinium‐chelate, gadobenate dimeglumine (MultiHance, MH), compared to a standard dose linear gadolinium chelate, gadodiamide (Omniscan, OM).

Materials and Methods:

This study was Health Insurance Portability and Accountability Act (HIPAA)‐compliant and Institutional Review Board (IRB)‐approved. As per institution standardized contrast‐enhanced magnetic resonance imaging (MRI) protocols, patients on dialysis were imaged using either MH, between 2/2007 to 9/2008, or OM between 10/2003 and 1/2007. Rates of NSF were compared using 95% score‐based confidence intervals (CI). The Wilcoxon rank sum test was used to test similarity/difference between contrast doses given to each patient group.

Results:

Overall, 312 patients on dialysis received OM and eight (2.6%) developed NSF (95% CI: 1.30%–4.98%). In all, 784 patients on dialysis received MH at a mean cumulative dose of 0.11 mmol/kg (0.05–0.75 mmol/kg) and no cases of NSF were identified (upper 95% confidence bound of 0.45%). The mean cumulative dose of OM was 0.16 mmol/kg (0.1–0.9 mmol/kg) for all patients and 0.28 mmol/kg (0.1–0.8 mmol/kg) for the patients with NSF. The median OM dose was greater in patients who developed NSF (P = 0.03), and was greater than the median MH dose (P < 0.005).

Conclusion:

NSF incidence in at‐risk patients receiving contrast‐enhanced MRI can be reduced after changing contrast administration protocols that includes changing the type and dose of contrast agent. J. Magn. Reson. Imaging 2010; 31: 440–446. © 2010 Wiley‐Liss, Inc.     

Contrast‐enhanced whole‐heart coronary MRI with bolus infusion of gadobenate dimeglumine at 1.5 T

We sought to investigate the T₁ kinetics of blood and myocardium after three infusion schemes of gadobenate dimeglumine (Gd‐BOPTA) and subsequently compared contrast‐enhanced whole‐heart coronary MRI after a bolus Gd‐BOPTA infusion with nonenhanced coronary MRI at 1.5 T. Blood and myocardium T₁ was measured in seven healthy adults, after each underwent three Gd‐BOPTA infusion schemes (bolus: 0.2 mmol/kg at 2 mL/sec, hybrid: 0.1 mmol/kg at 2 mL/sec followed by 0.1 mmol/kg at 0.1 mL/sec, and slow: 0.2 mmol/kg at 0.3 mL/sec). Fourteen additional subjects underwent contrast‐enhanced coronary MRI with an inversion‐recovery steady‐state free precession sequence after bolus Gd‐BOPTA infusion. Images were compared with nonenhanced T₂‐prepared steady‐state free precision whole‐heart coronary MRI in signal‐to‐noise ratio, contrast‐to‐noise ratio, depicted vessel length, vessel sharpness, and subjective image quality. Bolus and slow infusion schemes resulted in similar T₁ during coronary MRI, whereas the hybrid infusion method yielded higher T₁ values. A bolus infusion of Gd‐BOPTA significantly improved signal‐to‐noise ratio, contrast‐to‐noise ratio, depicted coronary artery length, and subjective image quality, when all segments were collectively compared but not when compared segment by segment. In conclusion, whole‐heart steady‐state free precision coronary MRI at 1.5 T can benefit from a bolus infusion of 0.2 mmol/kg Gd‐BOPTA. Magn Reson Med, 2011. © 2010 Wiley‐Liss, Inc.     

Gadobenate dimeglumine--a new contrast agent for MR imaging: preliminary evaluation in healthy volunteers.

Gadobenate dimeglumine (formerly known as Gd-BOPTA) is a recently developed paramagnetic contrast agent that undergoes biliary as well as renal excretion. It may, therefore, be useful in MR imaging of the liver. Its safety, tolerance, and usefulness in visualizing hepatobiliary structures were studied in eight healthy subjects. Axial abdominal images were obtained with T1-weighted spin-echo and gradient-echo sequences at 1.5 T before and after IV administration of gadobenate dimeglumine in doses of 0.005, 0.05, 0.1, and 0.2 mmol/kg body weight. Two subjects received each dose. Administration of 0.1 mmol/kg resulted in a maximum liver enhancement of 149% on the gradient-echo sequence and of 90% on the T1-weighted spin-echo sequence 60 min after injection. The contrast enhancement of the liver remained virtually constant for 2 hr. The signal-to-noise ratio of the biliary tract increased from 38 to 121 after 2 hr on gradient-echo images. In addition, there was significant contrast enhancement of the kidneys. Optimal visualization of the liver parenchyma was achieved with doses of 0.05 and 0.1 mmol gadobenate dimeglumine/kg. Mild to moderate side effects such as nausea and retching, a sense of warmth at the infusion site, and transient pruritus lasting 1 min were reported by three (38%) of the subjects. The initial results of the first application of gadobenate dimeglumine in humans are encouraging because the contrast agent appears to be reasonably well tolerated at the doses appropriate for hepatobiliary imaging. Further clinical studies of this contrast agent are warranted to assess its effect on liver lesion conspicuity and the frequency with which side effects occur.